News & Events

30 11, 2022

Join Avance Biosciences at the Gene Therapy Analytical Development Summit Nov 28 – Dec 1 2022

2022-11-30T15:03:21+00:00

Avance offers a broad range of assay development services, including assay design, assay validation, sample testing, and technology transfer under GLP compliance to support IND-enabling and clinical studies. With decades of experience helping gene and cell therapy companies, Avance Biosciences has the...

Join Avance Biosciences at the Gene Therapy Analytical Development Summit Nov 28 – Dec 1 20222022-11-30T15:03:21+00:00
22 11, 2022

Quantification of On/Off-Target Gene Editing

2022-11-22T16:37:58+00:00

Quantitative analysis of gene editing is now an essential step in getting regulatory approval of gene editing-based therapies. But designing and validating assays for on/off-target editing analysis and building an internal team to perform them can be costly and inefficient...

Quantification of On/Off-Target Gene Editing2022-11-22T16:37:58+00:00
9 11, 2022

CHOP Study Offers Proof of Concept for Treating Pediatric Brain Tumors with Immunotherapy

2022-11-09T12:34:59+00:00

Although immunotherapy has revolutionized the treatment of many blood cancers, the field has encountered challenges developing similar treatments for solid tumors. When it comes to pediatric brain tumors, which are the leading cause of cancer death in children, challenges include...

CHOP Study Offers Proof of Concept for Treating Pediatric Brain Tumors with Immunotherapy2022-11-09T12:34:59+00:00
1 11, 2022

Remarkable results from CAR-T cell therapy for lupus

2022-11-01T19:15:08+00:00

A recent study has shown remarkable results from compassionate use of CAR-T cell therapy to treat severe lupus in five patients in whom multiple other treatments had previously failed. CAR-T cell therapy involves genetically engineering T cells, a type of immune cell, so that they respond to a prespecified molecular marker, or antigen. This means they mount an immune response against cells with the chosen antigen...

Remarkable results from CAR-T cell therapy for lupus2022-11-01T19:15:08+00:00
26 10, 2022

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis

2022-10-26T14:30:28+00:00

Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis. Kyverna’s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate...

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis2022-10-26T14:30:28+00:00
18 10, 2022

A report on the state of the cell and gene therapy industry

2022-10-18T15:39:46+00:00

Twice a year, the Alliance for Regenerative Medicine (ARM) surveys the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to their members, their stakeholders, and the public at large. While external conditions ebb and flow, the sector’s progress — in clinical milestones, regulatory developments, and patient impact — steadily advances...

A report on the state of the cell and gene therapy industry2022-10-18T15:39:46+00:00
3 10, 2022

Join Avance Biosciences at the Cell & Gene Meeting on the Mesa Oct 11-13, 2022!

2022-10-18T15:38:20+00:00

Avance offers a broad range of assay development services, including assay design, assay validation, sample testing, and technology transfer under GLP compliance to support IND-enabling and clinical studies. With decades of experience helping gene and cell therapy companies, Avance Biosciences has the...

Join Avance Biosciences at the Cell & Gene Meeting on the Mesa Oct 11-13, 2022!2022-10-18T15:38:20+00:00
20 09, 2022

Join Avance Biosciences at Biotech Boston Sept 27-30, 2022!

2022-09-22T16:00:08+00:00

Ensure the Success of Your Biological Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Join Avance Biosciences at Biotech Boston Sept 27-30, 2022!2022-09-22T16:00:08+00:00
13 09, 2022

Kyverna Therapeutics’ $85 million series B financing reflects significant investor confidence in the science behind cell therapies

2022-09-12T19:53:36+00:00

Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures. Additional investors included the company’s founding investors Westlake Village BioPartners (“Westlake”), Vida Ventures, and Gilead Sciences (“Gilead”), with new investors RTW [...]

Kyverna Therapeutics’ $85 million series B financing reflects significant investor confidence in the science behind cell therapies2022-09-12T19:53:36+00:00
30 08, 2022

First allogeneic cell therapy candidate engineered to target cd19 for b-cell malignancies receives IND clearance, will proceed to clinical trials

2022-08-25T19:15:52+00:00

Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, announced today that the company has been notified by the U.S. Food and Drug Administration (FDA) that the Company’s ELiPSE-1 clinical study may proceed to assess CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies. CNTY-101 is [...]

First allogeneic cell therapy candidate engineered to target cd19 for b-cell malignancies receives IND clearance, will proceed to clinical trials2022-08-25T19:15:52+00:00